Before drafting a clinical protocol, I like to ask what we hope to say in the product labeling and what evidence we’ll need to support it.
That gives the team a way to evaluate the design. Does the primary endpoint measure the benefit we hope to describe? Are we enrolling the population we intend to treat? And for each additional assessment, what decision will the result inform? Every procedure adds some burden for participants and sites. It should earn its place.
Whether I’m writing the protocol myself or working with an experienced medical writer, I start with the current template appropriate to the study. Drafting can surface gaps between what the study aims to show and what sites will actually collect. That’s one reason I like to start the writing early, while there’s still time to address those gaps.
I apply the same discipline to amendments. What problem are we solving? Who will have to change how they work? What will it cost to implement? Could the change compromise the evidence we need for the intended labeling?
For example, shortening follow-up might save a visit for every participant and reduce site costs. It could also leave us without the data we need to show how long the benefit lasts. That trade-off deserves more discussion than the one line it takes to edit the schedule.
When a protocol is open for amendment, it’s tempting to revisit everything. I focus the team on changes that solve a substantive problem and make sure we understand the consequences before we commit.